Thursday, January 16, 2025 at 2-3pm ET                             Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Inflammatory Bowel Disease (IBD) is a chronic, progressive disease that damages the bowel over time and may result in decreased quality of life, hospitalizations, surgeries, and disability. The American Gastroenterological Association treatment guidelines for the treatment of ulcerative colitis have recently been updated and new living approach to the guidelines, along with a focus on long-term clinical and endoscopic goals for disease management have been established.

Background:

• The prevalence of IBD is higher in the US than any other country in the world and is increasing.
• An estimated 2.1 million Americans suffer from IBD.
• IBD damages the bowel and may result in decreased quality of life, hospitalizations, surgeries, and increased healthcare costs.
• IBD patients may develop an extra-intestinal manifestation.
• IBD symptoms are often unpredictable and are associated with a considerable clinical and economic burden.
• The AGA recently released living guidelines for the treatment of moderate to severe ulcerative colitis.

Learning Objectives

• Discuss the epidemiology of Inflammatory Bowel Disease and the associated clinical burden that often requires multiple treatment options for patients.
• Review the recently released AGA Living Guidelines for the treatment of moderate to severe ulcerative colitis in adults.
• Discuss the application of the updated ulcerative colitis guidelines, and the impact of disease progression, long-term outcomes, and economic burden of IBD.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.